Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Protalix BioTherapeutics (PLX) Leases (2019 - 2025)

Protalix BioTherapeutics has reported Leases over the past 7 years, most recently at $7.7 million for Q4 2025.

  • Quarterly results put Leases at $7.7 million for Q4 2025, up 41.8% from a year ago — trailing twelve months through Dec 2025 was $7.7 million (up 41.8% YoY), and the annual figure for FY2025 was $7.7 million, up 41.8%.
  • Leases for Q4 2025 was $7.7 million at Protalix BioTherapeutics, down from $7.8 million in the prior quarter.
  • Over the last five years, Leases for PLX hit a ceiling of $7.8 million in Q3 2025 and a floor of $4.8 million in Q2 2022.
  • Median Leases over the past 5 years was $5.4 million (2021), compared with a mean of $5.6 million.
  • Peak annual rise in Leases hit 41.8% in 2025, while the deepest fall reached 12.79% in 2025.
  • Protalix BioTherapeutics' Leases stood at $5.0 million in 2021, then increased by 2.56% to $5.1 million in 2022, then increased by 16.16% to $5.9 million in 2023, then dropped by 8.11% to $5.4 million in 2024, then skyrocketed by 41.8% to $7.7 million in 2025.
  • The last three reported values for Leases were $7.7 million (Q4 2025), $7.8 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.